Summer 2027

Business Strategy & Marketing Excellence Intern

Posted on 9/8/2026

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma focused on antibodies

Compensation Overview

$21 - $24/hr

No H1B Sponsorship

Princeton, NJ, USA

Hybrid

Requires at least two days on-site per week and residence within commuting distance of Princeton.

Bachelor's

Category
Business & Strategy (1)
Required Skills
Microsoft Office
Business Strategy
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Kyowa Kirin

See people who can refer or advise you

Requirements
  • Be a rising sophomore, junior, or senior pursuing a degree in Business Administration, Finance, Life Sciences, Marketing, Healthcare Management, or a related field.
  • Have strong academic performance with coursework in business, marketing, operations, strategy, project management, or related disciplines.
  • Be proficient in Microsoft Office, including Excel and PowerPoint.
  • Have strong analytical thinking, problem-solving, and organizational skills.
  • Have excellent written and verbal communication skills.
  • Be able to manage multiple priorities, work independently, and collaborate effectively across teams.
  • Have an interest in the pharmaceutical, biotechnology, or healthcare industry.
  • Have a minimum GPA of 3.0.
  • Be available to work for the full internship period from May 25, 2027 through August 20, 2027.
  • Be able to work a hybrid schedule and commute to the Princeton, New Jersey office as required.
  • Live within a commutable distance of Princeton, New Jersey.
  • Be authorized to work in the United States on a permanent and ongoing basis without sponsorship.
Responsibilities
  • Participate in strategy team meetings and contribute ideas for process improvements and project execution.
  • Support BrandForward and other brand planning and lifecycle management initiatives that drive marketing excellence and cross-functional collaboration.
  • Assist stakeholders across Communications, Government Affairs, Finance, Commercial Operations, and other functions in executing strategic business initiatives.
  • Research industry trends, policy developments, and business insights to support strategic decision-making.
  • Participate in learning and development opportunities to expand business and leadership skills.
  • Lead a meaningful internship project and present findings and recommendations to key stakeholders at the conclusion of the program.
Desired Qualifications
  • Prior internship, leadership, or project experience.

1) What does this company do? Kyowa Kirin develops specialty pharmaceutical drugs with a focus on nephrology, oncology, and immunology, built on a foundation of fermentation technology and antibody science. 2) How does this company's product(s) work? It uses fermentation-derived biology and antibody-based approaches to create therapies that target kidney disease, cancer, and immune-related conditions, delivered as approved medicines after research, development, and clinical testing. 3) How is this company different from its competitors? It blends deep fermentation and microbiology expertise with antibody technology from its history, plus a global specialty-drug focus, resulting from a merger of Kyowa Hakko Kogyo and Kirin Pharma that combined fermentation know-how with pharmaceutical resources. 4) What is this company's goal? To develop and commercialize innovative treatments that address unmet medical needs in nephrology, oncology, and immunology on a global scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Get referred to Kyowa Kirin

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA selected Sanford for PreCheck on June 30, 2026, accelerating biologics launch readiness.
  • Crysvita expanded adult XLH dosing in May 2026, extending treatment uptake and persistence.
  • 2025 revenue reached ¥496.8 billion, and 2026 guidance rises to ¥520.0 billion.

What critics are saying

  • Crysvita sales still dominate; any reimbursement squeeze or safety issue hits 2026 results fast.
  • Sanford slips past 2027, and the FDA PreCheck advantage evaporates into delay and cost.
  • March 2026 leadership turnover, including CFO Motohiko Kawaguchi, disrupts execution and accountability.

What makes Kyowa Kirin unique

  • Crysvita remains the only approved XLH therapy, protecting a rare-disease franchise in 2026.
  • Sanford, North Carolina gives Kyowa Kirin a first U.S. biologics manufacturing base by 2027.
  • Benchling deployment in Tokyo and Fuji formalizes AI-enabled R&D workflows across discovery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-2%
Yahoo Finance
Aug 26th, 2026
Cognizant wins Kyowa Kirin AI R&D deal to implement Benchling platform in Japan

Cognizant Technology Solutions will support Kyowa Kirin in implementing Benchling, an AI-driven R&D platform, at the Tokyo and Fuji Research Parks in Japan. The engagement includes platform setup, data migration, ongoing maintenance, and workflow optimization for drug discovery research. The deal reinforces Cognizant's enterprise-scale AI automation capabilities in life sciences digitalization. However, it is unlikely to shift near-term catalysts around broader AI adoption or risks that AI may erode demand for labour-intensive services. Cognizant's narrative projects $24.9 billion revenue and $3.1 billion earnings by 2029, requiring 5.2% yearly revenue growth. The most optimistic analysts forecast revenue reaching $26.1 billion and earnings of $3.9 billion by 2029, depending on how AI investments translate into higher-margin work.

IT Business Today
Aug 17th, 2026
Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation.

Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation. Last updated: August 17, 2026 12:53 pm Kyowa Kirin has chosen Cognizant and Benchling to support the rollout of Benchling's cloud-based R&D platform at its Tokyo Research Park and Fuji Research Park. The platform brings experimental planning, data collection, AI tools, and workflow automation into one place. Researchers can connect experimental equipment directly to Benchling, allowing data to be captured as structured and searchable records instead of being entered manually. That matters as Kyowa Kirin's research work becomes more complex and its pipeline expands. The company expects the platform to help speed up activities ranging from identifying drug targets to selecting new drug candidates. Researchers will also be able to search past experiments, generate reports, examine relationships between studies, and support molecular design using the platform's analytical and AI capabilities. Cognizant will handle the implementation using Benchling, including platform setup, data migration, deployment, and the ongoing upkeep too. This partnership shows where pharma research and development is headed, more or less, these days. More of the work around data handling and routine processes is being moved into connected digital systems, while AI is being brought closer to the research itself rather than treated as a separate tool. ITBT Staffwriter is an in-house contributor at IT Business Today, responsible for delivering timely News and QuickBytes. The author covers the latest developments across IT, tech, and enterprise solutions to keep readers informed with concise and impactful updates. August 17, 2026

Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.